Search
Search filters
Type
Audience
Category
Issue
Last updated
Recall class
Displaying 16 - 21 of 21 items.
FASLODEX (fulvestrant) - Risk of Unnecessary Therapy Modification due to Falsely Elevated Estradiol Levels
AlertHealth professional risk communication | 2016-10-18
Important Safety Information Regarding Reports of Serious Hepatic Events in Patients Receiving ACCOLATE® (Zafirlukast) – For Health Professionals
AlertHealth professional risk communication | 2004-04-19
SGLT2 Inhibitors [INVOKANA (canagliflozin), FORXIGA (dapagliflozin), XIGDUO (dapagliflozin/metformin), JARDIANCE (empagliflozin)] - Risk of Diabetic Ketoacidosis
AlertHealth professional risk communication | 2016-05-16
Archived – Important Safety Information Regarding Tamoxifen and Incidence of Uterine Malignancies, Stroke and Pulmonary Embolism
AlertHealth professional risk communication | 2002-11-07
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
AlertHealth professional risk communication | 2022-10-26
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
AlertHealth professional risk communication | 2023-01-17